Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Kidney Cancer Clinical Trials

A listing of Kidney Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (19) clinical trials

Imaging Study in Patients With Cancer of the Head & Neck Lung Renal Cell Brain Lymphoma and Neuroendocrine Tumours

The proposed clinical trial will be a Phase I/II imaging, open label, single site study. In Phase I, one 18F-FAZA PET scan will be conducted in patients with known squamous cell carcinoma of the Head & Neck, SCLC, NSCLC, lymphoma, GGM, neuroendocrine tumours or renal cell carcinoma. In Phase II, ...

Phase

MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to 1 of 4 dose levels based on when you join this study. The dose of MGCD516 you receive will depend on how well previously enrolled patients tolerated the study drug. ...

Phase

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer. The drugs being tested in this study have an anti-tumour effect and have been tested in pre-clinical ...

Phase

A Dose Escalation Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma

CDX-014 is an antibody-drug conjugate that binds to a protein called TIM-1, which is found on a high percentage of kidney cancer cells and other tumors. The study will enroll patients with advanced or metastatic renal cell carcinoma to determine the safety and efficacy of CDX-014. Eligible patients that enroll ...

Phase

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

PRIMARY OBJECTIVE: To assess in a preliminary fashion the feasibility and efficacy of ibrutinib in combination with nivolumab in patients with previously-treated metastatic renal cell cancer (mRCC). SECONDARY OBJECTIVE: To evaluate the safety of the combination of ibrutinib and nivolumab in patients with previously treated mRCC.

Phase

Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma

Treatment with immune checkpoint inhibitors, such as nivolumab, may result in the generation of anti-tumor immune responses. However, the objective radiological response in advanced RCC patients was only 21.5%. Therefore, it is important to identify additional therapies that could augment the anti-tumor immune activity of checkpoint inhibitors, resulting in an ...

Phase

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

The trial is being done in three parts: Part 1A (MEL and RCC) will define the maximum tolerated dose (MTD)/maximum administered dose (MAD) for the drug combinations; a recommended Phase 2 dose (RP2D) for each combination will be identified. Part 1B (MEL-single arm expansion) will better characterize safety and efficacy ...

Phase

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Varlilumab is a fully human monoclonal antibody that binds to a molecule called CD27 found on certain immune cells and may act to promote anti-tumor effects. Nivolumab is a fully human monoclonal antibody that binds to a molecule called PD-1 on immune cells and promotes anti-tumor effects. Eligible patients that ...

Phase

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

Sunitinib is an oral receptor tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptors (VEGFRs), platelet derived growth factor receptor (PDGFRs) and c-kit. Sunitinib was the first TKI to be approved for the first-line treatment of advanced kidney cancer on the grounds of the results achieved in the ...

Phase

A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in selected advanced gastrointestinal and genitourinary tumors.

Phase